View in EDS

1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer.

Saved in:
Bibliographic Details
Title: 1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer.
Authors: Rimmel, B.1 (AUTHOR), Bender, D.2 (AUTHOR), Enserro, D.3 (AUTHOR), Westin, S.4 (AUTHOR), Powell, M.A.5 (AUTHOR), Holman, L.6 (AUTHOR), Moore, R.G.7 (AUTHOR), Backes, F.8 (AUTHOR), Musa, F.B.9 (AUTHOR), DiSilvestro, P.10 (AUTHOR), Godbee, N.11 (AUTHOR), Gill, S.E.12 (AUTHOR), Leath III, C.A.13 (AUTHOR), Barber, E.14 (AUTHOR), Beffa, L.15 (AUTHOR), Aghajanian, C.16 (AUTHOR), Mackay, H.17 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS742-S742. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 189419558
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Rimmel%2C+B%2E%22">Rimmel, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bender%2C+D%2E%22">Bender, D.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Enserro%2C+D%2E%22">Enserro, D.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Westin%2C+S%2E%22">Westin, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Powell%2C+M%2EA%2E%22">Powell, M.A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Holman%2C+L%2E%22">Holman, L.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moore%2C+R%2EG%2E%22">Moore, R.G.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Backes%2C+F%2E%22">Backes, F.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Musa%2C+F%2EB%2E%22">Musa, F.B.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22DiSilvestro%2C+P%2E%22">DiSilvestro, P.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Godbee%2C+N%2E%22">Godbee, N.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gill%2C+S%2EE%2E%22">Gill, S.E.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leath+III%2C+C%2EA%2E%22">Leath III, C.A.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barber%2C+E%2E%22">Barber, E.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Beffa%2C+L%2E%22">Beffa, L.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aghajanian%2C+C%2E%22">Aghajanian, C.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mackay%2C+H%2E%22">Mackay, H.</searchLink><relatesTo>17</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS742-S742. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189419558
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2025.08.1752
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S742
    Titles:
      – TitleFull: 1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Rimmel, B.
      – PersonEntity:
          Name:
            NameFull: Bender, D.
      – PersonEntity:
          Name:
            NameFull: Enserro, D.
      – PersonEntity:
          Name:
            NameFull: Westin, S.
      – PersonEntity:
          Name:
            NameFull: Powell, M.A.
      – PersonEntity:
          Name:
            NameFull: Holman, L.
      – PersonEntity:
          Name:
            NameFull: Moore, R.G.
      – PersonEntity:
          Name:
            NameFull: Backes, F.
      – PersonEntity:
          Name:
            NameFull: Musa, F.B.
      – PersonEntity:
          Name:
            NameFull: DiSilvestro, P.
      – PersonEntity:
          Name:
            NameFull: Godbee, N.
      – PersonEntity:
          Name:
            NameFull: Gill, S.E.
      – PersonEntity:
          Name:
            NameFull: Leath III, C.A.
      – PersonEntity:
          Name:
            NameFull: Barber, E.
      – PersonEntity:
          Name:
            NameFull: Beffa, L.
      – PersonEntity:
          Name:
            NameFull: Aghajanian, C.
      – PersonEntity:
          Name:
            NameFull: Mackay, H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2025 Supplement 2
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 36
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1